GLP-1 medication failure rate, bariatric surgery failure rate, Ozempic discontinuation weight regain, weight loss surgery long-term success rate
Which Option Has the Higher Failure Rate Long-Term?
GLP-1 medications have a higher effective failure rate long-term, primarily because most patients stop taking them. Real-world data show 50% of obesity-only patients discontinue within 12 months, and 72% discontinue within two years. After stopping, most regain most of the weight within 12 to 18 months. Bariatric surgery has a lower failure rate — about 8% of patients fail to achieve 50% excess weight loss by 18 months, and about 23% meet composite failure definitions at five years — but surgery failure is about biology and behavior, not adherence to a prescription.
What "Failure" Means for Each Treatment
The word "failure" means something different for each treatment, which is why head-to-head failure rate comparisons require some care. For GLP-1 medications, failure most often means discontinuation — stopping the drug before achieving or sustaining meaningful weight loss. For surgery, failure means insufficient weight loss or significant regain despite completing the procedure.
This distinction matters because the two failure modes have different causes and different implications. GLP-1 failure is largely driven by cost, side effects, and insurance access — external factors that don't reflect the medication's biological effectiveness for patients who stay on it. Surgical failure is more about biological response and long-term behavioral factors, in a patient who completed a permanent anatomical change.
The failure rate comparison also matters differently depending on what a patient is trying to understand. If the question is "which option is more likely to still be working for me at five years," the answer is surgery, by a wide margin. If the question is "which option has an easier path to starting treatment," medication wins on accessibility.
GLP-1 Failure: The Discontinuation Problem
A 2024 JAMA Network Open study of real-world GLP-1 use found overall discontinuation rates of 26.2% at three months, 30.8% at six months, and 36.5% at 12 months. For patients with obesity but not diabetes — the population most directly comparable to bariatric surgery candidates — discontinuation at 12 months reached 50.3% (Weintraub et al., JAMA Network Open 2024). By two years, discontinuation across populations reaches approximately 72%, according to real-world matched cohort data.
What happens when patients stop matters as much as whether they stop. A 2026 claims database study found that 57% of patients who discontinued GLP-1 medications regained weight within a year, with average regain reaching 7.5% total body weight at 12 months (Weintraub et al., 2026, PMC13043475). A 2026 BMJ systematic review and meta-analysis of 37 studies found weight increased by an average of 0.8 kg per month after stopping newer GLP-1 agents, with projections showing return to baseline weight within approximately 18 months. Cardiometabolic markers — blood sugar, blood pressure, lipids — returned to baseline within about 14 months.
A 2025 real-world outcomes study found that patients who discontinued GLP-1 therapy early lost an average of only 3.6% of body weight at one year. Even patients who stayed on therapy for a full year averaged 11.9% total weight loss — meaningful, but substantially below the 15 to 20% seen in controlled trials, largely because real-world patients use lower doses and discontinue at higher rates than trial participants (Gasoyan et al., Obesity 2025).
Surgical Failure: What the Numbers Show
A large prospective study from the Tehran Obesity Treatment Study, covering 3,456 patients, defined insufficient weight loss as failing to achieve 50% excess weight loss by 18 months — the most commonly used clinical threshold. By that definition, 8% of patients experienced insufficient weight loss (Heidari Almasi et al., Langenbeck's Archives of Surgery 2025). Using a stricter threshold of less than 20% total weight loss, the rate was 2.9%.
Longer follow-up shows higher failure rates, particularly after sleeve gastrectomy. A Swedish registry study of gastric bypass patients found 23.1% met at least one definition of surgical treatment failure at five years, using composite criteria including excess BMI loss below 50%, total weight loss below 20%, or BMI remaining above 35 (BMJ Open 2021). A separate sleeve-specific analysis found weight loss failure rates of 35.2% at five years for standard (non-banded) sleeve gastrectomy.
A 2025 long-term comparative analysis found that bariatric surgery achieved 10-year total weight loss of 23.4% for sleeve and 26.9% for bypass — durable results that GLP-1 therapy, even at its best trial performance, approaches but doesn't match when real-world discontinuation is factored in (Brosnihan et al., American Journal of Surgery 2025).
Cumulative Success at Five Years
Putting the numbers together gives a clearer picture of what "still working at five years" looks like for each treatment. For gastric bypass, approximately 77% of patients meet success criteria at five years using composite definitions. For sleeve gastrectomy, approximately 65% meet success criteria at five years. Both figures reflect patients who remained in follow-up care, so loss to follow-up may affect the estimates.
For GLP-1 therapy, cumulative success at five years is much harder to estimate precisely, because so few patients remain on therapy at that point. At two years, only about 28% of real-world patients are still on medication. Among those who persist and use adequate doses, 12 to 18% total weight loss is achievable. Among early discontinuers, the average is 3 to 7%. Weighting by the proportion of patients in each group, the real-world five-year success rate for sustained meaningful weight loss with GLP-1 therapy is substantially lower than surgical success rates.
What This Means for How You Decide
These failure rates don't mean GLP-1 medication is a bad treatment. For patients who respond well, tolerate the drug, and sustain it long-term, it produces real and meaningful weight loss. But the real-world profile — high discontinuation, weight regain after stopping, and modest average outcomes across the full population of users — makes it a less reliable option at the population level than surgery for patients whose disease burden warrants sustained, durable intervention.
The surgical failure rate of 8% at 18 months and 23% at five years is real and worth discussing honestly. Predictors of surgical failure — higher baseline BMI, diabetes at the time of surgery, sleeve gastrectomy versus bypass — are identifiable in advance, which means procedure selection and pre-surgical optimization can meaningfully reduce individual failure risk. That's a different problem than GLP-1 failure, where the primary driver is a medication access and adherence problem that individual patients have limited control over.
Frequently Asked Questions
What percentage of GLP-1 patients stop the medication within a year?
Real-world data show 36.5% overall discontinuation at 12 months, rising to 50.3% among patients with obesity but not diabetes — the population most comparable to bariatric surgery candidates. By two years, discontinuation reaches approximately 72% across populations.
What happens to weight after stopping GLP-1 medication?
Most patients regain. A 2026 claims database study found 57% regained weight within a year of stopping, averaging 7.5% total body weight regained at 12 months. A 2026 BMJ meta-analysis found weight returned to baseline within approximately 18 months for patients on newer GLP-1 agents.
What percentage of bariatric surgery patients don't lose enough weight?
Using the most common clinical threshold — failing to achieve 50% excess weight loss by 18 months — about 8% of patients experience insufficient weight loss after surgery. At five years, using composite failure definitions, approximately 23% of gastric bypass patients and 35% of sleeve patients meet at least one failure criterion.
Does bypass have a lower failure rate than sleeve?
Yes. Multiple studies show bypass produces more durable weight loss with lower long-term failure rates than sleeve. At five years, sleeve failure rates run higher than bypass by most definitions. This is one of the factors we weigh when helping patients choose between the two procedures.
Which option is more likely to still be working at five years?
Surgery. Approximately 65 to 77% of surgical patients maintain meaningful weight loss at five years, depending on procedure. For GLP-1 therapy, only about 28% of real-world patients remain on medication at two years. Among the full population of people who start GLP-1 therapy, sustained meaningful weight loss at five years is achieved by a substantially smaller proportion than surgical success rates reflect.
Want to talk through which option has a better chance of working long-term for you specifically?
We see patients at every stage — researching, on medication, plateaued, or ready to discuss surgery. A consultation is the clearest way to find out where you stand.
Sources
- Weintraub HS, et al. GLP-1 Agonist Discontinuation Among Patients With Obesity and Diabetes: A National Real-World Study. JAMA Network Open. 2024. jamanetwork.com/journals/jamanetworkopen/fullarticle/2819256
- Gasoyan H, et al. Real-world weight loss outcomes with semaglutide and tirzepatide for obesity: the impact of treatment persistence and dosing. Obesity. 2025.
- Weintraub HS, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a real-world claims database study. 2026. pmc.ncbi.nlm.nih.gov/articles/PMC13043475
- Weight regain following the cessation of medication for weight management: a systematic review and meta-analysis. BMJ. 2026.
- Heidari Almasi M, Barzin M, Mahdavi M, et al. Insufficient weight loss after bariatric surgery and its predictors: Tehran Obesity Treatment Study (TOTS). Langenbeck's Archives of Surgery. 2025. DOI: 10.1007/s00423-025-03682-z. pmc.ncbi.nlm.nih.gov/articles/PMC11965242
- Prevalence of insufficient weight loss 5 years after Roux-en-Y gastric bypass: metabolic consequences and prediction estimates. BMJ Open. 2021;11:e046407. DOI: 10.1136/bmjopen-2020-046407.
- Brosnihan P, Luce MS, Yetasook AK, Perez C, Scharf KR, Aly S. Great debates: undergoing the knife versus pill-popping — the comparative efficacy and cost-effectiveness of bariatric surgery and GLP-1 receptor agonists. American Journal of Surgery. 2025. pubmed.ncbi.nlm.nih.gov/40285863